Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals Inc. (ELTP) specializes in advanced generic drug formulations with a focus on controlled-release oral medications. This news hub provides investors and industry professionals with essential updates on regulatory milestones, product developments, and strategic partnerships.
Access real-time announcements about FDA approvals, manufacturing expansions, and licensing agreements. Our curated collection includes earnings reports, clinical trial updates, and market entry strategies specific to ELTP's niche generics portfolio.
Discover how the company's DEA-registered facility and ANDA submissions position it in competitive therapeutic markets. Stay informed about innovations in pain management solutions and CNS disorder treatments through verified press releases.
Bookmark this page for streamlined access to ELTP's latest business developments. Regularly updated content ensures you never miss critical updates about this specialty pharmaceutical innovator.
Elite Pharmaceuticals (OTCQB: ELTP) has announced the commercial launch of its generic version of Tylenol with Codeine (acetaminophen and codeine phosphate) tablets. The product is available in three strengths: 300mg/15mg, 300mg/30mg, and 300mg/60mg. These tablets are indicated for managing mild to moderate pain where opioid treatment is appropriate and alternative treatments are inadequate.
The product is marketed and sold under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of acetaminophen and codeine in these strengths were approximately $47 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment for pain management medications.
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic methotrexate sodium 2.5 mg tablets. This medication is a dihydrofolate reductase inhibitor used to treat various conditions in adults and children, including acute lymphoblastic leukemia, rheumatoid arthritis, and severe psoriasis.
The product is marketed under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of methotrexate sodium 2.5 mg tablets were approximately $63 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment within the pharmaceutical industry.
Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q1 FY2025 ended June 30, 2024. Highlights include:
- Consolidated revenues of $18.8 million, up 109% year-over-year
- Operating profits of $3.9 million, increased 144% year-over-year
- Net income attributable to common shareholders of $0.6 million
The significant growth in operating profits was primarily due to higher sales of Elite label products. The company will host a conference call on August 15, 2024, at 11:30 AM EDT to discuss the results and provide business updates. Stockholders can submit questions in advance to dianne@elitepharma.com by August 14, 2024, 7:00 PM EDT.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, has announced its upcoming financial release and conference call schedule. The company will release its first quarter financial results for fiscal year 2025 on August 14, 2024. Following this, Elite's management will host a live conference call on August 15, 2024, at 11:30 AM EDT to discuss the financial and operating results, as well as provide a general business update.
Stockholders are encouraged to submit questions to the company prior to the call. The dial-in numbers for the conference are 1-800-346-7359 (domestic) and 1-973-528-0008 (international), with the conference number 98840. An audio replay will be available on the company's website.
Elite Pharmaceuticals announced its fiscal year-end results for March 31, 2024, showing a significant performance boost. The company reported consolidated revenues of $56.6 million, marking a 65% increase from the previous fiscal year. Operating profits surged by 192% to $10.8 million, largely due to the launch of the Elite label product line. Net income attributable to common shareholders stood at $20.1 million. Elite will host a conference call on July 2, 2024, at 11:30 AM EDT to discuss these results and recent business developments. Stockholders are encouraged to submit financial questions in advance.
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, announced they will release their fiscal year 2024 financial results on July 1, 2024. To discuss these results, Elite will host a live conference call on July 2, 2024, at 11:30 AM EDT. Shareholders are encouraged to submit their questions by June 28, 2024, for general queries, and by July 1, 2024, for financial queries. The conference call will provide an overview of financial and operating results along with a business update. The call can be accessed via specific dial-in numbers for domestic and international participants.
Elite Pharmaceuticals announced FDA approval for its generic Methotrexate Sodium 2.5 mg tablets. This approval relates to an Abbreviated New Drug Application (ANDA) and adds to Elite's portfolio of niche generic products. The generic Methotrexate, classified as an antimetabolite, will be marketed under Elite Laboratories. According to IQVIA, the generic market for Methotrexate had annual sales of $64.3 million for the twelve months ending March 2024. Elite Pharmaceuticals focuses on developing, manufacturing, and distributing immediate-release and controlled-release solid oral dose products, operating from a cGMP and DEA registered facility in Northvale, NJ.
FAQ
What is the current stock price of Elite Pharmaceuticals (ELTP)?
What is the market cap of Elite Pharmaceuticals (ELTP)?
